Davies FE - Search Results

1

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Weinhold N, et al. Among authors: davies fe. Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11. Blood. 2016. PMID: 27516441 Free PMC article.

2

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

3

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

4

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. Davies FE, et al. J Clin Oncol. 2000 Aug;18(15):2843-51. doi: 10.1200/JCO.2000.18.15.2843. J Clin Oncol. 2000. PMID: 10920132

5

Controversies surrounding the clonogenic origin of multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Br J Haematol. 2000 Jul;110(1):240-1. doi: 10.1046/j.1365-2141.2000.02072-6.x. Br J Haematol. 2000. PMID: 10931011 Free article. No abstract available.

6

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P. Rawstron AC, et al. Among authors: davies fe. Blood. 2001 Jul 1;98(1):29-35. doi: 10.1182/blood.v98.1.29. Blood. 2001. PMID: 11418459 Free article.

7

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Davies FE, et al. Blood. 2001 Jul 1;98(1):210-6. doi: 10.1182/blood.v98.1.210. Blood. 2001. PMID: 11418482 Free article.

8

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC. Podar K, et al. Among authors: davies fe. Blood. 2001 Jul 15;98(2):428-35. doi: 10.1182/blood.v98.2.428. Blood. 2001. PMID: 11435313 Free article.

9

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Barrans SL, et al. Among authors: davies fe. Blood. 2002 Feb 15;99(4):1136-43. doi: 10.1182/blood.v99.4.1136. Blood. 2002. PMID: 11830458 Free article.

10

Minimal residual disease monitoring in multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Best Pract Res Clin Haematol. 2002 Mar;15(1):197-222. doi: 10.1053/beha.2002.0192. Best Pract Res Clin Haematol. 2002. PMID: 11987924 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page